Shirzad Fatemeh, Morovatdar Negar, Rezaee Ramin, Tsarouhas Konstantinos, Abdollahi Moghadam Alireza
Department of Cardiology, Emam Reza Educational Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Equal first author.
Avicenna J Phytomed. 2021 Jan-Feb;11(1):91-100.
Cinnamon effect on blood pressure remains controversial. The present pilot study assessed cinnamon effect on blood pressure, and metabolic profile of stage 1 hypertension patients (S1HTN).
This double-blind placebo-controlled randomized trial was conducted between June and October 2019, in Mashhad, Iran. Study inclusion criteria comprised S1HTN diagnosis, based on 24-hour ambulatory blood pressure monitoring (ABPM). Subjects were randomly assigned to two groups: cinnamon group (capsule, 1500 mg/day, 90 days) and placebo group. On days 0 and 90, ABPM derived systolic and diastolic blood pressure (SBP and DBP, respectively), blood lipid profile, and fasting blood sugar (FBS) were recorded.
The two groups did not differ significantly regarding vascular risk factors, educational status, lipid profile and blood pressure at baseline, except for lower HDL-c in cinnamon group (p=0.03). On day 90, there was no significant difference between two study groups for lipid profile and blood pressure. A statistically significant decrease in mean 24-hr SBP and mean day SBP was observed in the cinnamon group, while mean night SBP and mean night DBP were decreased significantly in the placebo group after 90 days. A statistically significant decrease in mean change of day value of SBP was found in the cinnamon group, compared to the placebo. On day 90, FBS remained practically unchanged but a significant increase in HDL-c (5.8 unit; p=0.01) and a significant decrease in LDL-c levels (17.7 unit; p=0.009) were observed in the cinnamon group compared to placebo group.
Cinnamon caused a statistically significant decrease in mean ambulatory SBP but in a clinically moderate way, and lipid profile was significantly improved. Therefore, cinnamon might be considered a complementary treatment in subjects with S1HTN.
肉桂对血压的影响仍存在争议。本初步研究评估了肉桂对1期高血压患者(S1HTN)血压及代谢指标的影响。
本双盲安慰剂对照随机试验于2019年6月至10月在伊朗马什哈德进行。研究纳入标准包括基于24小时动态血压监测(ABPM)诊断为S1HTN。受试者被随机分为两组:肉桂组(胶囊,1500毫克/天,90天)和安慰剂组。在第0天和第90天,记录ABPM得出的收缩压和舒张压(分别为SBP和DBP)、血脂谱和空腹血糖(FBS)。
两组在基线时的血管危险因素、教育程度、血脂谱和血压方面无显著差异,但肉桂组的高密度脂蛋白胆固醇(HDL-c)较低(p = 0.03)。在第90天,两个研究组在血脂谱和血压方面无显著差异。肉桂组观察到24小时平均SBP和日间平均SBP有统计学意义的下降,而安慰剂组在90天后夜间平均SBP和夜间平均DBP显著下降。与安慰剂组相比,肉桂组SBP日间值的平均变化有统计学意义的下降。在第90天,FBS基本保持不变,但与安慰剂组相比,肉桂组HDL-c显著升高(5.8单位;p = 0.01),低密度脂蛋白胆固醇(LDL-c)水平显著下降(17.7单位;p = 0.009)。
肉桂使动态平均SBP有统计学意义的下降,但临床下降程度适中,且血脂谱显著改善。因此,肉桂可被视为S1HTN患者的辅助治疗方法。